Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell Carcinoma

NCT06364631 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.

NCT NCT06364631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06364631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell Carcinoma
Lead sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Phase
Phase 3
Overall status
Recruiting
Start date
April 12, 2024
Completion date
May 5, 2032
Enrollment
1,250 (estimated)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic kidney cancer, metastatic kidney carcinoma